Advertisement

BioDrugs

, Volume 33, Issue 2, pp 221–228 | Cite as

In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima®) Following Preparation for Intravenous Infusion and Storage

  • Su Jung Kim
  • Kwang Woo Kim
  • Yeon Kyeong Shin
  • Ji Woong Kwon
  • Hye Young Kang
  • Yoon A. Park
  • Ji Young Shin
  • So Young KimEmail author
  • Won Yong Han
Short Communication
  • 202 Downloads

Abstract

Background

CT-P10 is the first biosimilar of the anti-CD20 monoclonal antibody, rituximab. CT-P10 is currently available in over 51 countries worldwide, where it is approved in the same indications as its reference product rituximab. In-use stability studies are conducted for biologics to determine how conditions (e.g., temperature, light, humidity, length of time stored) affect drug quality following dilution and storage in infusion bags.

Objective

We evaluated the in-use stability of CT-P10 for intravenous infusion stored diluted in infusion bags over longer periods than currently recommended by manufacturer guidelines.

Methods

CT-P10, within the final month of its 36-month shelf life, was diluted to 1.0 or 4.0 mg/mL and stored at 2–8 °C in polyethylene or polyvinylchloride infusion bags for 2, 4, and 6 weeks. CT-P10 infusion bags were incubated at room temperature for 24 h before analysis. Analyses included detection of sub-visible particles, formation of impurities and determination of charge variants, and heavy- and light-chain content. Cell-based CD20 binding affinity and complement-dependent cytotoxicity were also assessed.

Results

Diluted CT-P10 solutions remained clear, colorless, and free of visible particles irrespective of type of infusion bag, target concentration, or timepoint. Protein concentrations, sub-visible particles, pH, osmolality, and molecular weight and charge variants were stable across all timepoints and variables. The binding affinity and potency of CT-P10 remained unchanged, indicating that the efficacy of the antibody was maintained following in-use preparation.

Conclusions

We demonstrated that CT-P10 was stable after refrigerated storage for up to 6 weeks followed by incubation at room temperature.

Notes

Acknowledgements

Medical writing support (including development of a draft outline and subsequent drafts in consultation with the authors, assembling tables, collating author comments, copyediting, fact checking, and referencing) was provided by Emma Evans, PhD at Aspire Scientific Limited (Bollington, UK), and funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Drafts were reviewed by Sang-Wook Yoon, PhD and Dasom Choi at Celltrion Healthcare Co., Ltd.

Author Contributions

SJK and WYH were involved in the conception and design of the study. SJK, KWK, YKS, JWK, HYK, YAP, and JYS were involved in the acquisition of data and/or analysis and interpretation of the data. SJK, KWK, YKS, JWK, HYK, YAP, JYS, and SYK reviewed drafts of the manuscript and approved the final version for submission. Won Yong Han will serve as the guarantor for the overall content.

Compliance with Ethical Standards

Funding

This study was sponsored by CELLTRION, Inc. (Incheon, Republic of Korea). Funding for medical writing assistance was provided by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea).

Conflict of interest

Su Jung Kim, Kwang Woo Kim, Yeon Kyeong Shin, Ji Woong Kwon, Hye Young Kang, Yoon A. Park, Ji Young Shin, So Young Kim, and Won Yong Han are employees of CELLTRION, Inc. The authors have no other conflicts of interest related to this work.

Data availability

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Supplementary material

40259_2019_336_MOESM1_ESM.pdf (121 kb)
Supplementary material 1 (PDF 121 kb)

References

  1. 1.
    Deeks ED. CT-P10 (Truxima): a rituximab biosimilar. BioDrugs. 2017;31(3):275–8.CrossRefGoogle Scholar
  2. 2.
    Storz U. Rituximab: how approval history is reflected by a corresponding patent filing strategy. MAbs. 2014;6(4):820–37.CrossRefGoogle Scholar
  3. 3.
    World Health Organisation. WHO model list of essential medicines. 20th list. 2017. http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1. Accessed 28 Aug 2018.
  4. 4.
    European Medicines Agency. Truxima summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf. Accessed 6 Aug 2018.
  5. 5.
    European Medicines Agency. MabThera summary of product characteristics. 2003. https://ec.europa.eu/health/documents/community-register/2005/2005111510665/anx_10665_en.pdf. Accessed 28 Aug 2018.
  6. 6.
    CELLTRION, Inc. Truxima™ 100mg package leaflet. 2017. http://www.celltrion.com/resources/pdf/CT-P10%20100mg_Leaflet(EN)_final(432x498)(CLT).pdf. Accessed 6 Aug 2018.
  7. 7.
    CELLTRION, Inc. Truxima™ 500mg package leaflet. 2017. http://www.celltrion.com/resources/pdf/CT-P10%20500mg_Leaflet(UK_IE)_final(432x498)(CLT).pdf. Accessed 6 Aug 2018.
  8. 8.
    European Medicines Agency. Truxima assessment report. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004112/WC500222695.pdf. Accessed 6 Aug 2018.
  9. 9.
    International Conference on Harmonisation Guideline. Stability testing of new drug substances and products Q1A(R2). 2003. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf. Accessed 6 Aug 2018.
  10. 10.
    International Conference on Harmonisation Guideline. Stability testing of biotechnological/biological products Q5C. 1995. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.pdf. Accessed 6 Aug 2018.
  11. 11.
    Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kabakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci. 2012;101(1):21–30.CrossRefGoogle Scholar
  12. 12.
    Mazzeo A, Carpenter P. Stability studies for biologics. In: Huynh-Ba K, editor. Handbook of stability testing in pharmaceutical development. New York: Springer; 2009. p. 353.CrossRefGoogle Scholar
  13. 13.
    Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98(4):1201–5.CrossRefGoogle Scholar
  14. 14.
    Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11(2):99–109.CrossRefGoogle Scholar
  15. 15.
    Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. MAbs. 2011;3(3):253–63.CrossRefGoogle Scholar
  16. 16.
    Zhang Y, Vermeulen LC, Kolesar JM. Stability of stock and diluted rituximab. Am J Health Syst Pharm. 2013;70(5):436–8.CrossRefGoogle Scholar
  17. 17.
    Paul M, Vieillard V, Jaccoulet E, Astier A. Long-term stability of diluted solutions of the monoclonal antibody rituximab. Int J Pharm. 2012;436(1–2):282–90.CrossRefGoogle Scholar
  18. 18.
    Vieillard V, Paul M, Ibrahim T, Astier A. Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags. Ann Pharm Fr. 2017;75(6):420–35.CrossRefGoogle Scholar
  19. 19.
    Lamanna WC, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, et al. The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion. J Oncol Pharm Pract. Epub 2017 Jan 1.  https://doi.org/10.1177/1078155217731506.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Su Jung Kim
    • 1
  • Kwang Woo Kim
    • 1
  • Yeon Kyeong Shin
    • 1
  • Ji Woong Kwon
    • 1
  • Hye Young Kang
    • 1
  • Yoon A. Park
    • 1
  • Ji Young Shin
    • 1
  • So Young Kim
    • 1
    Email author
  • Won Yong Han
    • 1
  1. 1.Biotechnology Research Institute, R&D DivisionCELLTRION, Inc.IncheonRepublic of Korea

Personalised recommendations